Posterior Reversible Encephalopathy Syndrome After Self-Medication With an Oral Decongestant: A Case Report.

end-stage renal disease oral decongestant posterior reversible encephalopathy syndrome self-medication sepsis

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2022
Historique:
received: 16 12 2021
accepted: 09 02 2022
entrez: 24 3 2022
pubmed: 25 3 2022
medline: 25 3 2022
Statut: epublish

Résumé

Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder caused by the dysregulation of cerebral perfusion. We report on a 18-year-old female patient with a history of end-stage renal disease and thrice weekly hemodialysis. She was admitted to the emergency department with mental confusion, blurred vision, headaches, and vomiting, following self-medication with an oral decongestant containing pseudoephedrine. We observed hypointense lesions with T1-weighted MRI and hyperintense areas with T2-weighted and fluid-attenuated inversion recovery MRI sequences. The lack of diffusion restriction was consistent with a diagnosis of PRES. A concomitant PRES is a life-threatening condition that requires intensive care. Identification of the etiology is the keystone of medical care. Inappropriate self-medication with an oral decongestant might trigger PRES - highlighting the importance of patient education.

Identifiants

pubmed: 35321464
doi: 10.3389/fmed.2022.837324
pmc: PMC8935013
doi:

Types de publication

Case Reports

Langues

eng

Pagination

837324

Informations de copyright

Copyright © 2022 Zerbib, Gibert, Bennis, Masmoudi, Maizel and Brault.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Intensive Care Med. 2007 Feb;33(2):230-6
pubmed: 17119920
ACG Case Rep J. 2020 Sep 29;7(9):e00459
pubmed: 33062792
Arch Intern Med. 2005 Aug 8-22;165(15):1686-94
pubmed: 16087815
Mol Neurobiol. 2019 Oct;56(10):6792-6806
pubmed: 30924075
Pharmacotherapy. 1993 Nov-Dec;13(6 Pt 2):116S-128S; discussion 143S-146S
pubmed: 7507589
AJR Am J Roentgenol. 2007 Oct;189(4):904-12
pubmed: 17885064
Clin Pharm. 1984 Nov-Dec;3(6):638-43
pubmed: 6509877
Pract Neurol. 2011 Jun;11(3):136-44
pubmed: 21551107
Autoimmun Rev. 2015 Sep;14(9):830-6
pubmed: 25999210
AJNR Am J Neuroradiol. 2008 Jun;29(6):1036-42
pubmed: 18356474
Can J Cardiol. 2017 May;33(5):688.e1-688.e3
pubmed: 28347584

Auteurs

Yoann Zerbib (Y)

Intensive Care Unit, Amiens University Medical Center, Amiens, France.

Louis Gibert (L)

Intensive Care Unit, Amiens University Medical Center, Amiens, France.

Youssef Bennis (Y)

Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, UR UPJV 7517, Amiens, France.

Kamel Masmoudi (K)

Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, France.

Julien Maizel (J)

Intensive Care Unit, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, UR UPJV 7517, Amiens, France.

Clément Brault (C)

Intensive Care Unit, Amiens University Medical Center, Amiens, France.

Classifications MeSH